The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition

eLife

Volumn 5, Issue APRIL2016, 2016, Pages

  Praissman, Jeremy L ^a   Willer, Tobias ^b,c   Osman Sheikh, M ^a   Toi, Ants ^d   Chitayat, David ^d,e,f   Lin, Yung Yao ^g,h   Lee, Hane ^i,j   Stalnaker, Stephanie H ^a   Wang, Shuo ^a   Prabhakar, Pradeep Kumar ^a   Nelson, Stanley F ^i,j   Stemple, Derek L ^h   Moore, Steven A ^b   Moremen, Kelley W ^a   Campbell, Kevin P ^b,c   Wells, Lance ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DYSTROGLYCAN; GLYCAN DERIVATIVE; PEPTIDES AND PROTEINS; PROTEIN P53; RIBITOL; TMEM5 PROTEIN; UNCLASSIFIED DRUG; DAG1 PROTEIN, HUMAN; DYSTROGLYCAN; ISPD PROTEIN, HUMAN; MANNOSE; MEMBRANE PROTEIN; NUCLEOTIDYLTRANSFERASE; POLYSACCHARIDE; PROTEIN BINDING; TMEM5 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANIMAL MODEL; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; MISSENSE MUTATION; MUSCULAR DYSTROPHY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; WESTERN BLOTTING; ANIMAL; CHEMISTRY; EXTRACELLULAR MATRIX; METABOLISM; ZEBRA FISH;

ANIMALS; DYSTROGLYCANS; EXTRACELLULAR MATRIX; HUMANS; MANNOSE; MEMBRANE PROTEINS; NUCLEOTIDYLTRANSFERASES; POLYSACCHARIDES; PROTEIN BINDING; RIBITOL; ZEBRAFISH;

EID: 84979503456     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.14473     Document Type: Article

References (60)

1. Adzhubei I, Jordan DM, Sunyaev SR. 2013. Predicting functional effect of human missense mutations using polyphen-2. Curr Protoc Hum Genet Chapter 7, Unit 7 20: 7.20.1-7.20.7. doi: 10.1002/0471142905.hg0720s76.
2. Baddiley J, Buchanan JG, Carss B, Mathias A.P, Sanderson AR. 1956. The isolation of cytidine diphosphate glycerol, cytidine diphosphate ribitol and mannitol 1-phosphate from lactobacillus arabinosus. The Biochemical Journal 64: 599-603. doi: 10.1042/bj0640599.
3. Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH. 2012. NMR characterization of immunoglobulin G fc glycan motion on enzymatic sialylation. Biochemistry 51: 4618-4626. doi: 10.1021/bi300319q.
4. Barresi R, Michele DE, Kanagawa M, Harper HA, Dovico SA, Satz JS, Moore SA, Zhang W, Schachter H, Dumanski JP, Cohn RD, Nishino I, Campbell KP. 2004. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nature Medicine 10: 696-703. doi: 10.1038/nm1059.
5. Baur S, Marles-Wright J, Buckenmaier S, Lewis RJ, Vollmer W. 2009. Synthesis of cdp-activated ribitol for teichoic acid precursors in streptococcus pneumoniae. Journal of Bacteriology 191: 1200-1210. doi: 10.1128/JB.01120-08.
6. Beckett D, Kovaleva E, Schatz PJ. 1999. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Science 8: 921-929. doi: 10.1110/ps.8.4.921.
7. Beltrán-Valero de BernabéD, Currier S, Steinbrecher A, Celli J, van Beusekom E, van der Zwaag B, Kayserili H, Merlini L, Chitayat D, Dobyns WB, Cormand B, Lehesjoki AE, Cruces J, Voit T, Walsh CA, van Bokhoven H, Brunner HG. 2002. Mutations in the o-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder walker-warburg syndrome. American Journal of Human Genetics 71: 1033-1043. doi: 10.1086/342975.
8. Carmignac V, Durbeej M. 2012. Cell-matrix interactions in muscle disease. The Journal of Pathology 226: 200-218. doi: 10.1002/path.3020.
9. Chiba A, Matsumura K, Yamada H, Inazu T, Shimizu T, Kusunoki S, Kanazawa I, Kobata A, Endo T. 1997. Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. The Journal of Biological Chemistry 272: 2156-2162.
10. Cirak S, Foley AR, Herrmann R, Willer T, Yau S, Stevens E, Torelli S, Brodd L, Kamynina A, Vondracek P, Roper H, Longman C, Korinthenberg R, Marrosu G, Nürnberg P, Michele DE, Plagnol V, Hurles M, Moore SA, Sewry CA, et al. 2013. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain 136: 269-281. doi: 10.1093/brain/aws312.
11. Collins BE, Yang LJ, Mukhopadhyay G, Filbin MT, Kiso M, Hasegawa A, Schnaar RL. 1997. Sialic acid specificity of myelin-associated glycoprotein binding. The Journal of Biological Chemistry 272: 1248-1255. doi: 10.1074/jbc.272.2.1248.
12. Damerell D, Ceroni A, Maass K, Ranzinger R, Dell A, Haslam SM. 2015. Annotation of glycomics MS and MS/MSspectra using the glycoworkbench software tool. Methods in Molecular Biology 1273: 3-15. doi: 10.1007/978-1-4939-2343-4_1.
13. Dobson CM, Hempel SJ, Stalnaker SH, Stuart R, Wells L. 2013. O-mannosylation and human disease. Cellular and Molecular Life Sciences 70: 2849-2857. doi: 10.1007/s00018-012-1193-0.
14. Dong M, Noguchi S, Endo Y, Hayashi YK, Yoshida S, Nonaka I, Nishino I. 2015. DAG1 mutations associated with asymptomatic hyperckemia and hypoglycosylation of α-dystroglycan. Neurology 84: 273-279. doi: 10.1212/WNL.0000000000001162.
15. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP. 1998. Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. The Journal of Cell Biology 142: 1461-1471. doi: 10.1083/jcb.142.6.1461.
16. Endo T, Manya H. 2006. O-mannosylation in mammalian cells. Methods in Molecular Biology 347: 43-56. doi: 10.1385/1-59745-167-3: 43.
17. Endo T. 2015. Glycobiology of α-dystroglycan and muscular dystrophy. Journal of Biochemistry 157: 1-12. doi: 10.1093/jb/mvu066.
18. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. 1990. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315-319. doi: 10.1038/345315a0.
19. Ervasti JM, Campbell KP. 1991. Membrane organization of the dystrophin-glycoprotein complex. Cell 66: 1121-1131. doi: 10.1016/0092-8674(91)90035-W.
20. Fakhouri M, Elalayli M, Sherling D, Hall JD, Miller E, Sun X, Wells L, LeMosy EK. 2006. Minor proteins and enzymes of the drosophila eggshell matrix. Developmental Biology 293: 127-141. doi: 10.1016/j.ydbio.2006.01.028.
21. Geis T, Marquard K, Rödl T, Reihle C, Schirmer S, von Kalle T, Bornemann A, Hehr U, Blankenburg M, Rödl T, Blankenburg M. 2013. Homozygous dystroglycan mutation associated with a novel muscle-eye-brain disease-like phenotype with multicystic leucodystrophy. Neurogenetics 14: 205-213. doi: 10.1007/s10048-013-0374-9.
22. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, Kanagawa M, Beltrán-Valero de BernabéD, Gündeşli H, Willer T, Satz JS, Crawford RW, Burden SJ, Kunz S, Oldstone MB, Accardi A, Talim B, Muntoni F, Topaloğlu H, Dinçer P, Campbell KP. 2011. A dystroglycan mutation associated with limb-girdle muscular dystrophy. The New England Journal of Medicine 364: 939-946. doi: 10.1056/NEJMoa1006939.
23. Hara Y, Kanagawa M, Kunz S, Yoshida-Moriguchi T, Satz JS, Kobayashi YM, Zhu Z, Burden SJ, Oldstone MB, Campbell KP. 2011. Like-acetylglucosaminyltransferase (large)-dependent modification of dystroglycan at thr-317/319 is required for laminin binding and arenavirus infection. Proceedings of the National Academy of Sciences of the United States of America 108: 17426-17431. doi: 10.1073/pnas.1114836108.
24. Holt KH, Crosbie RH, Venzke DP, Campbell KP. 2000. Biosynthesis of dystroglycan: Processing of a precursor propeptide. FEBS Letters 468: 79-83. doi: 10.1016/S0014-5793(00)01195-9.
25. Jae LT, Raaben M, Riemersma M, van Beusekom E, Blomen VA, Velds A, Kerkhoven RM, Carette JE, Topaloglu H, Meinecke P, Wessels MW, Lefeber DJ, Whelan SP, van Bokhoven H, Brummelkamp TR. 2013. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 340: 479-483. doi: 10.1126/science.1233675.
26. Kanagawa M, Kobayashi K, Tajiri M, Manya H, Kuga A, Yamaguchi Y, Akasaka-Manya K, Furukawa J, Mizuno M, Kawakami H, Shinohara Y, Wada Y, Endo T, Toda T. 2016. Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. Cell Reports 14: 2209-2223. doi: 10.1016/j.celrep.2016.02.017.
27. Kumagai T, Katoh T, Nix DB, Tiemeyer M, Aoki K. 2013. In-gel b-elimination and aqueous-organic partition for improved O- and sulfoglycomics. Analytical Chemistry 85: 8692-8699. doi: 10.1021/ac4015935.
28. Lee H, Jen JC, Cha YH, Nelson SF, Baloh RW. 2008. Phenotypic and genetic analysis of a large family with migraine-associated vertigo. Headache 48: 1460-1467. doi: 10.1111/j.1526-4610.2007.01002.x.
29. Lee H, O’Connor BD, Merriman B, Funari VA, Homer N, Chen Z, Cohn DH, Nelson SF. 2009. Improving the efficiency of genomic loci capture using oligonucleotide arrays for high throughput resequencing. BMCGenomics 10: 646: 646. doi: 10.1186/1471-2164-10-646.
30. Lee JK, Matthews RT, Lim JM, Swanier K, Wells L, Pierce JM. 2012. Developmental expression of the neuron-specific n-acetylglucosaminyltransferase vb (GnT-Vb/IX) and identification of its in vivo glycan products in comparison with those of its paralog, GnT-V. The Journal of Biological Chemistry 287: 28526-28536. doi: 10.1074/jbc.M112.367565.
31. Lefeber DJ, Schönberger J, Morava E, Guillard M, Huyben KM, Verrijp K, Grafakou O, Evangeliou A, Preijers FW, Manta P, Yildiz J, Grünewald S, Spilioti M, van den Elzen C, Klein D, Hess D, Ashida H, Hofsteenge J, Maeda Y, van den Heuvel L, et al. 2009. Deficiency of Dol-P-man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. American Journal of Human Genetics 85: 76-86. doi: 10.1016/j.ajhg.2009.06.006.
32. Link V, Shevchenko A, Heisenberg CP. 2006. Proteomics of early zebrafish embryos. BMC Developmental Biology 6: 1. doi: 10.1186/1471-213X-6-1.
33. Manzini MC, Tambunan DE, Hill RS, Yu TW, Maynard TM, Heinzen EL, Shianna KV, Stevens CR, Partlow JN, Barry BJ, Rodriguez J, Gupta VA, Al-Qudah AK, Eyaid WM, Friedman JM, Salih MA, Clark R, Moroni I, Mora M, Beggs AH, et al. 2012. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of walker-warburg syndrome. American Journal of Human Genetics 91: 541-547. doi: 10.1016/j.ajhg.2012.07.009.
34. Meng L, Forouhar F, Thieker D, Gao Z, Ramiah A, Moniz H, Xiang Y, Seetharaman J, Milaninia S, Su M, Bridger R, Veillon L, Azadi P, Kornhaber G, Wells L, Montelione GT, Woods RJ, Tong L, Moremen KW. 2013. Enzymatic basis for n-glycan sialylation: Structure of rat a2,6-sialyltransferase (ST6GAL1) reveals conserved and unique features for glycan sialylation. The Journal of Biological Chemistry 288: 34680-34698. doi: 10.1074/jbc.M113.519041.
35. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP. 2002. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418: 417-421. doi: 10.1038/nature00837.
36. Muntoni F, Torelli S, Wells DJ, Brown SC. 2011. Muscular dystrophies due to glycosylation defects: Diagnosis and therapeutic strategies. Current Opinion in Neurology 24: 437-442. doi: 10.1097/WCO.0b013e32834a95e3.
37. Parsons MJ, Campos I, Hirst EM, Stemple DL. 2002. Removal of dystroglycan causes severe muscular dystrophy in zebrafish embryos. Development 129: 3505-3512.
38. Perl A, Hanczko R, Telarico T, Oaks Z, Landas S. 2011. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends in Molecular Medicine 17: 395-403. doi: 10.1016/j.molmed.2011.01.014.
39. Praissman JL, Wells L. 2014. Mammalian o-mannosylation pathway: Glycan structures, enzymes, and protein substrates. Biochemistry 53: 3066-3078. doi: 10.1021/bi500153y.
40. Praissman JL, Live DH, Wang S, Ramiah A, Chinoy ZS, Boons GJ, Moremen KW, Wells L. 2014. B4GAT1 is the priming enzyme for the LARGE-dependent functional glycosylation of α-dystroglycan. eLife 3:e03943. doi: 10.7554/eLife.03943.
41. Pédelacq JD, Cabantous S, Tran T, Terwilliger TC, Waldo GS. 2006. Engineering and characterization of a superfolder green fluorescent protein. Nature Biotechnology 24: 79-88. doi: 10.1038/nbt1172.
42. Richard SB, Bowman ME, Kwiatkowski W, Kang I, Chow C, Lillo AM, Cane DE, Noel JP. 2001. Structure of 4-diphosphocytidyl-2-c- methylerythritol synthetase involved in mevalonate- independent isoprenoid biosynthesis. Nature Structural Biology 8: 641-648. doi: 10.1038/89691.
43. Riemersma M, Froese DS, van Tol W, Engelke UF, Kopec J, van Scherpenzeel M, Ashikov A, Krojer T, von Delft F, Tessari M, Buczkowska A, Swiezewska E, Jae LT, Brummelkamp TR, Manya H, Endo T, van Bokhoven H, Yue WW, Lefeber DJ. 2015. Human ISPD is a cytidyltransferase required for dystroglycan o-mannosylation. Chemistry & Biology 22: 1643-1652. doi: 10.1016/j.chembiol.2015.10.014.
44. Riemersma M, Sandrock J, Boltje TJ, Büll C, Heise T, Ashikov A, Adema GJ, van Bokhoven H, Lefeber DJ. 2015. Disease mutations in cmp-sialic acid transporter SLC35A1 result in abnormal α-dystroglycan o-mannosylation, independent from sialic acid. Human Molecular Genetics 24: 2241-2246. doi: 10.1093/hmg/ddu742.
45. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, Ekker SC. 2007. p53 activation by knockdown technologies. PLoS Genetics 3:e78. doi: 10.1371/journal.pgen.0030078.
46. Roscioli T, Kamsteeg EJ, Buysse K, Maystadt I, van Reeuwijk J, van den Elzen C, van Beusekom E, Riemersma M, Pfundt R, Vissers LE, Schraders M, Altunoglu U, Buckley MF, Brunner HG, Grisart B, Zhou H, Veltman JA, Gilissen C, Mancini GM, Delrée P, et al. 2012. Mutations in ISPD cause walker-warburg syndrome and defective glycosylation of α-dystroglycan. Nature Genetics 44: 581-585. doi: 10.1038/ng.2253.
47. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. 2012. SIFT web server: Predicting effects of amino acid substitutions on proteins. Nucleic Acids Research 40:W452-457. doi: 10.1093/nar/gks539.
48. Stalnaker SH, Hashmi S, Lim JM, Aoki K, Porterfield M, Gutierrez-Sanchez G, Wheeler J, Ervasti JM, Bergmann C, Tiemeyer M, Wells L. 2010. Site mapping and characterization of o-glycan structures on alpha-dystroglycan isolated from rabbit skeletal muscle. The Journal of Biological Chemistry 285: 24882-24891. doi: 10.1074/jbc.M110.126474.
49. Stalnaker SH, Stuart R, Wells L. 2011. Mammalian o-mannosylation: Unsolved questions of structure/function. Current Opinion in Structural Biology 21: 603-609. doi: 10.1016/j.sbi.2011.09.001.
50. Tözsér J, Tropea JE, Cherry S, Bagossi P, Copeland TD, Wlodawer A, Waugh DS, Tözsér J, Waugh DS. 2005. Comparison of the substrate specificity of two potyvirus proteases. The FEBS Journal 272: 514-523. doi: 10.1111/j.1742-4658.2004.04493.x.
51. Vester-Christensen MB, Halim A, Joshi HJ, Steentoft C, Bennett EP, Levery SB, Vakhrushev SY, Clausen H. 2013. Mining the o-mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. Proceedings of the National Academy of Sciences of the United States of America 110: 21018-21023. doi: 10.1073/pnas.1313446110.
52. Vuillaumier-Barrot S, Bouchet-Séraphin C, Chelbi M, Devisme L, Quentin S, Gazal S, Laquerrière A, Fallet-Bianco C, Loget P, Odent S, Carles D, Bazin A, Aziza J, Clemenson A, Guimiot F, Bonnière M, Monnot S, Bole-Feysot C, Bernard JP, Loeuillet L, et al. 2012. Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. American Journal of Human Genetics 91: 1135-1143. doi: 10.1016/j.ajhg.2012.10.009.
53. Wells L. 2013. The o-mannosylation pathway: Glycosyltransferases and proteins implicated in congenital muscular dystrophy. The Journal of Biological Chemistry 288: 6930-6935. doi: 10.1074/jbc.R112.438978.
54. Willer T, Lee H, Lommel M, Yoshida-Moriguchi T, de Bernabe DB, Venzke D, Cirak S, Schachter H, Vajsar J, Voit T, Muntoni F, Loder AS, Dobyns WB, Winder TL, Strahl S, Mathews KD, Nelson SF, Moore SA, Campbell KP. 2012. ISPD loss-of-function mutations disrupt dystroglycan o-mannosylation and cause walker-warburg syndrome. Nature Genetics 44: 575-580. doi: 10.1038/ng.2252.
55. Willer T, Inamori K, Venzke D, Harvey C, Morgensen G, Hara Y, Beltrán Valero de BernabéD, Yu L, Wright KM, Campbell KP. 2014. The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated α-dystroglycan functional glycosylation. eLife 3:e03941. doi: 10.7554/eLife.03941.
56. Yoshida M, Ozawa E. 1990. Glycoprotein complex anchoring dystrophin to sarcolemma. Journal of Biochemistry 108: 748-752.
57. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, Mizuno M, Inazu T, Mitsuhashi H, Takahashi S, Takeuchi M, Herrmann R, Straub V, Talim B, Voit T, Topaloglu H, Toda T, Endo T. 2001. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, pomgnt1. Developmental Cell 1: 717-724. doi: 10.1016/S1534-5807(01)00070-3.
58. Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, Madson M, Oldstone MBA, Schachter H, Wells L, Campbell KP. 2010. O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.. Science 327: 88-92. doi: 10.1126/science.1180512.
59. Yoshida-Moriguchi T, Willer T, Anderson ME, Venzke D, Whyte T, Muntoni F, Lee H, Nelson SF, Yu L, Campbell KP. 2013. SGK196 is a glycosylation-specific o-mannose kinase required for dystroglycan function. Science 341: 896-899. doi: 10.1126/science.1239951.
60. Yoshida-Moriguchi T, Campbell KP. 2015. Matriglycan: A novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 25: 702-713. doi: 10.1093/glycob/cwv021.